Large-scale testing (Phase 3)Active Not RecruitingNCT05732805
What this trial is testing
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Who this might be right for
MelanomaMelanoma (Skin)Melanoma Stage III+4 more
Biocad 270